Inside 340B Report

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the comments submitted to the Health Resources and Services Administration (HRSA) in response to the agency's 340B rebate request for information (RFI); what Congress and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had to say about 340B rebates and the program, in general; and key legal developments with major 340B implications. Key Topics Covered: Rebate RFI Wraps Up Will breaks down the avalanche of responses to HRSA's RFI seeking comments on whether to implement a future 340B rebate model leading up to the agency's April 20 deadline. He notes that the submissions came against the backdrop of federal court rulings that blocked HRSA's initial 340B rebate pilot proposal from taking effect Jan. 1, as many providers and manufacturers were likely writing their comments anticipating a potential future legal challenge if HRSA attempts to implement a new rebate model. Congress and Kennedy on Rebates Luke and Will discuss competing letters circulating in Congress relating to a potential federal 340B rebate model. Shannon discusses what appeared to be Kennedy's first public comments on 340B rebates, which came during a series of Capitol Hill appearances he made on the Trump administration's fiscal year 2027 HHS budget proposal. Shannon also highlights the secretary's criticism of how some 340B hospitals use program savings, as well as praise he shared for the program while fielding lawmakers' questions. Luke talks about a Senate committee hearing on drug pricing at which a witness pushed to end the 340B program's current structure and replace it with a direct subsidy program. Key Legal Developments Will breaks down a Richmond, Va.-based federal appeals court's 2-1 decision against Maryland's 340B contract pharmacy access law. He notes that the same three judges on the Maryland case also recently decided against West Virginia's similar 340B contract pharmacy access law. Will explains that those two decisions were the first appellate rulings to side with manufacturers, after three-judge federal appeals court panels unanimously upheld similar laws in Arkansas, Louisiana and Mississippi. Ted and Will also discuss whether the appeals court will grant West Virginia officials' recent request for a full panel rehearing. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. We are very grateful to Visante for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including 340B stakeholder reactions to a provider hearing in the U.S. House and ongoing discussion over a 2027 fiscal year (FY) federal spending package that could include language blocking 340B rebates. The team also discusses major updates in the states, including a newly enacted first-of-its-kind 340B law in the Pacific Northwest, a controversial effort to kill a 340B bill in the Midwest and a closer look into state prescription drug affordability boards (PDABs). Key Topics Covered: Capitol Hill Update Shannon and Luke discuss a recent House Energy & Commerce (E&C) Health Subcommittee hearing on providers' role in health care costs, which focused on the 340B program, among other things. Shannon breaks down what two of the witnesses had to say about the drug discount program. Luke highlights the questions key lawmakers asked witnesses, as well as how two senior Republican committee members called for 340B reforms and support for their 340B ACCESS Act, which has drawn major pushback from provider groups. Shannon also offers an update on the FY 2027 federal appropriations process taking shape on Capitol Hill, noting that a group of bipartisan House lawmakers is pushing to add language to the health spending bill that would block a 340B rebate model's implementation. Key State Developments Will discusses "the tale of two states," where high-profile 340B bills in Washington and Kansas faced very different outcomes. He also discusses two recent federal district court rulings in favor of state contract pharmacy laws, which continued a string of mostly favorable legal rulings for the states. Deep Dive into PDABs Luke discusses PDABs that are popping up across the states and their potential implications on the 340B program. At least 11 states have created a PDAB or a similar board tasked with addressing high drug prices, with some states granting that board to set upper payment limits on drugs. Luke shares why experts say PDABs could lead to lower 340B savings for covered entities, as well as other impacts on the drug supply chain. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to hello@proximityhealth.com. We are very grateful to Proximity for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's national correspondent, break down the latest in 340B news, including the Trump administration's high-profile entrance into the fight over state 340B contract pharmacy access laws. The team also discusses updates in the federal government's consideration of a potential new 340B rebate pilot, President Donald Trump's recent calls to codify most-favored nation (MFN) pricing agreements and the 340B Coalition's winter conference and National Association of Community Health Centers' (NACHC) Policy & Issues Forum. Key Topics Covered: Contract Pharmacy Restrictions Fight Heats Up Will discusses the Trump administration's unexpected move to file amicus briefs supporting two drugmaker legal challenges to state 340B contract pharmacy access laws in Colorado and Rhode Island. He explains that most federal court rulings on contract pharmacy access laws have sided with the states, noting it is unclear to what extent the federal government's briefs will affect this trend. Will also notes that two U.S. Justice Department lawyers who signed the briefs previously represented drugmakers in drug pricing litigation, including one who served as a drugmaker's counsel in cases on 340B contract pharmacy use and 340B rebates. Rebate Model Update Luke, Shannon and Will discuss the latest developments in the federal government's consideration of a potential new 340B rebate model after court action halted the initial pilot from taking effect. They break down the latest regulatory actions surrounding that effort, including the White House's Office of Management and Budget's review of a prerule and the Health Resources and Services Administration's (HRSA) subsequent issuance of a request for information and an information collection request—and how stakeholders have responded to them. Will offers insights into what HRSA's possible new rebate model could look like based off of these documents. MFN Codification Push Shannon highlights the Trump administration's recent push to codify MFN principles into federal law, including the president's State of Union call for Congress to pass such legislation and Centers for Medicare and Medicaid Services Administrator Mehmet Oz's similar comments during a Pharmaceutical Research and Manufacturers of America (PhRMA) forum. She notes pushback such efforts have garnered from PhRMA, which has instead urged lawmakers to focus on reforming pharmacy benefit managers and the 340B program. Conference Recaps Will shares his key takeaways from the Winter 340B Coalition Conference in San Diego, including provider concerns with manufacturer actions they argue are threatening the 340B program. He also discusses health policy experts' takes on the program, including what to expect from Congress and the Trump administration in the coming months. Luke discusses HRSA Administrator Tom Engels' comments at NACHC's forum. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, Associate Editors and Senior Writers Shannon Young and Will Newton join Luke Zarzecki, 340B Report's new national correspondent, in breaking down the latest in 340B news, including the Department of Health and Human Services' (HHS) move to officially drop its appeal in a case that halted the 340B rebate pilot program and a new federal spending bill that includes funding for key departments overseeing the 340B program, as well as for community health centers. They also discuss new drugmaker 340B contract pharmacy and maximum fair price (MFP) policies, and Luke introduces himself. Key Topics Covered: Rebate Case Update Will provides the latest on the 340B rebate debate, including HHS' decision to drop its appeal of a Maine federal judge's injunction halting the agency's 340B rebate pilot program. That means HHS still cannot implement its 340B rebate pilot as originally planned. But, as Will notes, it does not mean the broader debate over 340B rebates is settled. He shares that attorneys who have represented both 340B providers and the drug industry do not expect drugmakers or HHS to abandon their efforts to pursue 340B rebate models. Federal Funding Package Shannon and Luke break down a new bipartisan congressional health care package and what it could mean for the 340B program. Shannon discusses a U.S. House-approved spending bill and how much it allocated for key agencies that oversee the 340B program. She also details the highly anticipated funding figures for community health centers, which are largely funded by the federal government, and notes that it doesn't include a Trump administration proposal to move 340B program oversight from the Health Resources and Services Administration to the Centers for Medicare and Medicaid Services. Luke discusses the pharmacy benefit manager (PBM) reform provisions included in the legislation and their 340B implications. Shannon also notes that congressional leaders, who authored the appropriations bill, signaled concerns with the 340B rebate pilot program and requested an update from HRSA within one month in a bipartisan document released in conjunction with the spending package. Drugmaker Policies Will and Shannon discuss recent drugmaker policy developments. Will details Eli Lilly's new policy that would require all covered entities to submit claims data on 340B utilization at in-house pharmacies in a major shift that drew strong provider backlash. Shannon discusses Johnson & Johnson's interim plan to address "deduplication" between 340B discounts and the MFP without the 340B rebate pilot. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton breaking down the latest in 340B news, including a new hospital lawsuit aiming to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot, HRSA's recent webinar about that program, key regulatory updates on Medicare negotiated drug prices and a finalized hospital outpatient rule with significant implications for 340B hospitals and other stakeholders. Key Topics Covered: Hospitals Continue to Oppose Rebate Pilot Will breaks down a hospital group's new lawsuit urging a Maine federal district court to block HRSA from implementing its 340B rebate pilot ahead of its Jan. 1, 2026 launch. He also provides an update on separate 340B rebate litigation before a Washington, D.C. federal appeals court. Shannon highlights a new letter from a different national hospital group urging HRSA to address key concerns with the pilot. Technical Issues Disrupt HRSA's Rebate Webinar Will explains the technical issues that hampered HRSA's highly anticipated Dec. 4 webinar on its 340B rebate pilot program, preventing many stakeholders from joining. He then shares details of the second half of HRSA's webinar that 340B Report was able to access and notes 340B Report will provide additional coverage of the full webinar once it becomes available. CMS Lists New Negotiated Medicare Prices, Finalizes OPPPS Rule Shannon breaks down the Centers for Medicare and Medicaid Services' (CMS) late-November release of the "maximum fair price" (MFP) it will pay for 15 high-cost Medicare Part D drugs starting in 2027, and how those negotiated prices are expected to compare to the drugs' 340B ceiling prices. She and Ted also discuss 340B provider advocates' concerns with CMS' finalized 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, which includes a Medicare drugs acquisition cost survey and plan to accelerate outpatient payment cuts to offset previous 340B hospital lump sum repayments. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by PharmaForce. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) recent approval of drugmaker 340B rebate pilot plans—and the reactions they sparked; major court actions affecting Oklahoma and Colorado's 340B contract pharmacy access laws; and what Abigail Spanberger's (D) Virginia gubernatorial win could mean for 340B policy in that state. Key Topics Covered: Rebate Pilot Model Plans Approved, Unveiled Will provides an in-depth look at the manufacturer rebate pilot plans that HRSA approved, as well as provider frustrations over the pilot's rollout. Shannon breaks down the contrasting reactions to HRSA's plan approvals. 340B providers panned the move and the drug industry embraced it, urging that the model be expanded. She also teases a Dec. 15 340B Report subscriber-only webinar that will focus on the rebate pilot model's implementation. Federal Courts Block Oklahoma's Contract Pharmacy Law, Back Colorado's Will discusses a pair of conflicting federal district court rulings on 340B contract pharmacy access laws in two states. One judge blocked Oklahoma from enforcing its law while the drug industry litigation plays out, while a different judge denied AbbVie's bid to block enforcement of Colorado's statute. Despite the Oklahoma federal court's ruling, Shannon notes that some drugmakers are exempting covered entities in that state from their contract pharmacy restrictions. Virginia's Gubernatorial Election Implications Shannon breaks down how Spanberger's recent gubernatorial win could bolster advocates' efforts to enact 340B contract pharmacy protections in Virginia. She and Ted discuss Spanberger's leadership on 340B issues in Congress and how the Democrat made prescription drug pricing a key tenet of her 2025 campaign for governor. They also compare Spanberger's actions on 340B to outgoing Gov. Glenn Youngkin (R), who vetoed a widely supported, bipartisan 340B contract pharmacy access bill in 2024 after pressure from a dark-money group. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the ongoing federal government shutdown's impact on 340B operations, the latest in the 340B rebate debate and a large drugmaker's move to tighten 340B restrictions on certain hospitals that it believes are not complying with the company's current contract pharmacy policy. Key Topics Covered: Federal Government Shutdown Could Affect 340B Program Operations Shannon explains how the federal government shutdown has led to furloughs at the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs—and what that could mean for stakeholders if the shutdown drags on. She also discusses how the shutdown could impact a key upcoming deadline in HRSA's 340B rebate pilot program. Meanwhile, Ted shares his thoughts on politically-charged language about the shutdown that appeared on HRSA's website and the shutdown's real world effects on the HRSA staff and other federal workers. 340B Rebate Pilot Concerns and Upcoming Exclusive 340B Report Webinar Will discusses 340B stakeholders' continued implementation concerns with HRSA's controversial 340B rebate pilot program, including potentially significant financial and administrative burdens for providers. Will and Ted also preview 340B Report's exclusive, subscriber-only webinar on the biggest implementation questions for 340B stakeholders, which will take place on Oct. 15 and include a panel of experts from across the 340B supply chain. Pfizer Tightens 340B Restrictions, Makes Headlines with 'MFN' Move Shannon discusses Pfizer's recent move informing certain 340B hospitals that they could lose their approved one contract pharmacy exemption registered with industry vendor 340B ESP as of Nov. 1. She also explains Pfizer's headline-grabbing move to offer its drugs to Medicaid at a "most favored nation" price and launch a direct-to-consumer prescription drug platform. Shannon discusses why industry observers don't think it will have as significant an impact as it has been heralded by the White House and Pfizer executives. And why some stakeholders view those moves as undermining the drug industry's arguments that 340B drives higher drug prices. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the 1,000-plus public comments on the Health Resources and Services Administration's (HRSA) 340B rebate pilot proposal, the 340B ACCESS Act's reintroduction in Congress and a new Congressional Budget Office (CBO) report on 340B program growth, which has drawn criticism from provider advocates. Shannon and Will also provide updates on oral arguments in key federal cases that recently went before appeals court judges. Key Topics Covered: More than 1,000 Stakeholders Weigh-in on HRSA's 340B Rebate Pilot Proposal Will discusses the more than 1,200 stakeholder comments HRSA received over its contentious 340B rebate pilot proposal. He explains why hundreds of 340B providers urged the agency to abandon the rebate pilot altogether and discusses the drug industry's push to expand the pilot to more drugs. Will also breaks down stakeholders' concerns with the one-week turnaround between the comment due date and manufacturers' deadline to submit rebate proposals. CBO Report and ACCESS Act Reintroduction Take Center Stage on Capitol Hill Shannon breaks down the latest version of the 340B ACCESS Act, a controversial 340B overhaul bill which two key House GOP lawmakers reintroduced on Sept. 10. She discusses how the National Association of Community Health Centers has backed off from supporting the measure, which contains many of the provisions included in the May 2024 original version that providers advocates have vocally opposed. Shannon notes that the bill's reintroduction came one day after the nonpartisan CBO released a report on 340B program growth. Ted highlights provider advocates' criticisms of the report and why they believe it misses the mark. Appeals Courts Hear Arguments in Key 340B-Related Cases Will breaks down a trio of oral arguments that recently took place in federal appeals courts over drug industry challenges to state 340B contract pharmacy access laws. The hearings centered on whether the 340B statute's silence on drug delivery allows states to pass contract pharmacy access measures, and the judges asked tough questions of all parties. Shannon provides an update on recent oral arguments in a 5th Circuit Court of Appeals case surrounding a Centers for Medicare and Medicaid Services rule which could affect some hospitals' 340B program eligibility. A group of Texas hospitals have challenged the rule. A Texas federal District Court in 2024 declared it "unlawful" and halted its enforcement. HHS appealed the decision. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial. Listen to our newest podcast 340B Leaders Upfront We encourage you to check out 340B Report's new business area podcast, 340B Leaders Upfront, formerly 340B 360°, hosted by Anna Mangum. In the latest episode, Anna interviews two of the leaders of Plenful, an AI service provider company that is providing very cost-effective and highly beneficial services for the 340B provider community.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including updates to the comment deadline on the Health Resources and Services Administration's (HRSA) 340B rebate guidance—and why 340B stakeholders say the agency's timeline is not long enough. They also reflect on the implications of a major ruling in an antitrust lawsuit that two health centers filed against drug manufacturers, which were among the first companies to impose 340B contract pharmacy restrictions. The team also discusses new 340B enrollment requirements for sexually transmitted disease (STD) clinics. And Will breaks down a new 340B Report analysis that raises questions about the controversial alliance between the National Association of Community Health Centers (NACHC) and Pharmaceutical Research and Manufacturers of America (PhRMA). Key Topics Covered: HRSA Extends Rebate Pilot Comment Period and HHS Touts Model Shannon offers a recap on HRSA's proposed 340B rebate pilot program, including which drugs would qualify and when manufacturers can deny claims. She discusses a legal filing in which the Health and Human Services (HHS) Department touts its rebate model pilot plan, and she highlights HRSA's recent deadline extension for public comments on the proposal. Ted notes 340B providers' concerns with the rebate model, and why they're asking the agency to extend its consideration timeline for such proposals. Antitrust Case Ruling Sets Stage for Future Litigation Shannon highlights a recent federal appeals court ruling that 340B provider attorneys argue could open the door for future 340B-related lawsuits against drug manufacturers. The U.S. 2nd Circuit Court of Appeals overturned a lower court decision, unanimously ruling that an antitrust class action lawsuit can continue in a lower court. Two community health centers allege in the lawsuit that four major drugmakers illegally colluded to deny 340B pricing on insulin and other diabetes medicines through contract pharmacy restrictions. Ted discusses the legal background surrounding the case and its potential importance. STD Clinic Lawsuits and New Eligibility Requirements Will breaks down multiple lawsuits related to the 340B eligibility of a Nevada-based STD clinic, including multiple sites that HRSA terminated and later reinstated. Shannon notes that a new HRSA proposal would require STD clinics and other 340B covered entities to submit new or more complete information to enroll in or be re-certified in the 340B program. The proposal came just weeks after Office of Pharmacy Affairs (OPA) Director Chantelle Britton hinted at changes affecting STD clinics. Analysis Raises Questions about ASAP 340B Alliance Will discusses his recent analysis of the 340B reform alliance, called ASAP 340B, between the NACHC and PhRMA. Since the two groups formed their unlikely alliance in March 2023, the number of PhRMA member companies that have placed 340B restrictions on health centers has more than doubled—raising questions over how much the alliance has actually benefited NACHC members. Will also breaks down how NACHC's public posture on the alliance has appeared to shift, even as ASAP 340B continues its advocacy efforts and NACHC continues to be listed as one of its founding members. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne, the only independent provider of integrated pharmacy solutions. VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. Visit VytlOne to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 20: Reconciliation Bill's 340B Impact, CMS' Big 340B Proposals and Rebate Update In this episode, 340B Report Publisher & CEO Ted Slafsky and 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest 340B news, including key developments in Washington D.C., a federal 340B rebate court case and the ongoing lobbying effort of the White House's Office of Management and Budget over a potential rebate model. Ted closes the episode with a touching tribute to his late mentor David Gergen. Key Topics Covered: Reconciliation Bill Becomes Law, Key Congressional Subpanel Updates Leaders Shannon and Will discuss the recent enactment of the GOP-backed reconciliation bill, known as the "Big Beautiful Bill," including what its massive health spending cuts over the next decade could mean for 340B providers. Shannon highlights how 340B-related provisions stripped from the wide-ranging spending legislation have been reintroduced as part of a large bipartisan standalone bill focused on the Pharmacy Benefit Manager industry. And Ted discusses recent leadership changes on the House Energy and Commerce Health Subcommittee following U.S. Rep. Buddy Carter's (R-Ga.) decision to step down as chair as he runs for U.S. Senate. CMS Proposes Rules With Major 340B Implications Shannon and Will break down how two new Centers for Medicare and Medicaid Services (CMS) proposed rules would affect the 340B program. Shannon offers an overview of CMS' Outpatient Prospective Payment System (OPPS) draft rule and its significant implications for the 340B community. It contains controversial provisions to accelerate hospital outpatient payment cuts to offset previous 340B hospital lump sum repayments, as well as plans to survey hospital acquisition costs for certain outpatient medications. Next, Will discusses CMS' proposal to establish, for the first time, claims-based approaches to identifying 340B claims billed to Medicare Part D. 340B Rebate Model Debates Heats Up Will discusses the latest in drug industry efforts to implement controversial 340B rebate models. Four drugmakers are currently appealing a pair of lower courts' rebate rulings, while dozens of program stakeholders—including drugmakers, providers and technology vendors—are meeting with federal officials in an effort to sway highly anticipated federal 340B rebate guidance. Tribute to David Gergen Ted offers a touching tribute to David Gergen, his first mentor and boss out of college. Gergen was a senior adviser to four U.S. presidents and a highly influential editor and political commentator. Ted reflects on his inspiring career and shares his thoughts on his mentorship. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 18: Impending Rebate Guidance, Possible 340B Move from HRSA to CMS & Oklahoma's Veto Override In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the U.S. Department of Health and Human Services' (HHS) submission of 340B rebate guidance for regulatory review, a proposal to shift 340B oversight to the Centers for Medicare & Medicaid Services (CMS), U.S. Sen. Bill Cassidy's (R-La.) latest comments on 340B and Oklahoma's 340B contract pharmacy legislation veto override. In This Episode: Rebate Updates Will provides an update on the latest surrounding drugmakers' attempts to convert upfront 340B discounts to a post-purchase rebate model. He discusses HHS' June 1 submission of proposed 340B rebate guidance to the Office of Management and Budget, which will remain confidential throughout the review. Meanwhile, drugmakers Novartis and Bristol Myers Squibb filed an emergency motion to expedite their legal challenge to a ruling that affirms the government's authority to pre-approve 340B rebate models—citing looming compliance deadlines under the Inflation Reduction Act. A Proposed Shift to CMS and Other Federal Happenings Shannon and Ted break down President Donald Trump's full HHS budget request that calls for moving the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs (OPA), which oversees the 340B program, to CMS. They discuss the differences between the formal proposal and a version included in a leaked document, as well as 340B stakeholders' reaction to such a move. Shannon and Ted also discuss key federal players on 340B, including Cassidy's latest remarks on potential congressional reform plans and the return to the private sector of Katie Miller, a Trump adviser tied to a dark-money group running anti-340B ads in various states. The State of the States Will recaps Oklahoma's path to enacting a contract pharmacy access law, which included a gubernatorial veto and legislative override. He and Bella discuss the latest state-level action on 340B bills, as well as how drugmakers have responded to Tennessee's unique contract pharmacy access law. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce sponsored this week's episode. PharmaForce is the only Third Party Administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editor and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including developments in two major 340B lawsuits, new state contract pharmacy access laws with unique twists and developments on health funding negotiations and drug pricing policy talks in Washington, D.C. Key Topics Covered: Courts Hear Arguments in 340B Rebate, Antitrust Lawsuits Will recaps the latest developments in a key 340B rebate lawsuit, including recent oral arguments in which the drug industry argued it doesn't need federal approval to institute rebate models. HHS has told the drug manufacturers that they are not allowed to unilaterally implement a rebate model and a hospital group has intervened to oppose the use of rebates. The judge grilled attorneys representing both the drug industry and the Department of Health and Human Services (HHS). HHS later committed to issuing guidance on a rebate model—and what conditions, if any, they could be permitted—within the next few weeks. Bella recaps the recent oral arguments in a 340B antitrust case against four major insulin manufacturers. Ted and Bella discuss the significant implications of this case for 340B covered entities, should the appeals court side with the two health centers that have accused drugmakers of colluding on contract pharmacy restrictions. More States Advance Contract Pharmacy Bills Will provides an overview of recent contract pharmacy access bill developments in Oklahoma, Colorado and Hawaii. He notes some of the unique provisions contained in those bills, such as new reporting requirements for providers. Drug Pricing Talks Loom Large Shannon breaks down the latest developments on Capitol Hill as congressional Republicans work to wrap up wide-ranging spending legislation, which calls for $880 billion in health spending cuts that are largely expected to target Medicaid. The White House has proposed tying Medicaid drug prices to the prices paid in other affluent countries—a policy which has drawn pushback from both the drug industry and provider advocates. Ted recalls a similar initiative President Donald Trump pursued in his first term to tie dozens of Medicare Part B drugs prices to their international equivalents. Shannon also discusses new federal drug pricing legislation and Trump's HHS budget blueprint. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Maxor sponsored this week's episode. From specialty pharmacies to comprehensive pharmacy management, Maxor optimizes the pharmacy experience for patients and partners. We are very grateful to Maxor for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the latest states to enact contract pharmacy access laws, updates in key lawsuits and new U.S. Department of Health and Human Services (HHS) restructuring efforts. Key Topics Covered: New State Contract Pharmacy Access Laws Will highlights new contract pharmacy access laws enacted in Nebraska and Utah, including when they take effect and how their respective state governors approached the legislation. He also briefly discusses New Mexico's newly enacted contract pharmacy access law, which does not take effect until 2026 and is the only enacted state contract pharmacy protection statute that only applies to health centers. Key Updates in Drug Industry Lawsuits and State Enforcement Action Will also breaks down a Minnesota federal district judge's order to dismiss two drug industry lawsuits challenging that state's contract pharmacy access law. The judge ruled that the drugmakers had no legal standing to sue the state over its contract pharmacy law since Minnesota's law—unlike most other existing state contract pharmacy protection statutes—has no enforcement mechanism. Meanwhile, in Arkansas, a state official recently ordered AstraZeneca to restore access to 340B drugs at all contract pharmacy locations. AstraZeneca had been the only major manufacturer not to comply with Arkansas' first-in-the-nation contract pharmacy access law after a federal appeals court panel unanimously upheld the statute in March 2024. A New CMS Leader and HHS Restructuring Shannon and Bella provide an update on 340B-related activity at the federal level. Bella discusses the U.S. Senate's recent confirmation of Mehmet Oz as the new administrator of the Centers for Medicare and Medicaid Services (CMS). Shannon highlights the recent restructuring at HHS and rumored efforts to move the 340B program into CMS. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.